Administration Seeks to Stabilize Health Agency with Traditional Pick
President Trump has selected Erica Schwartz, a former Deputy Surgeon General and career public health officer, to lead the Centers for Disease Control and Prevention. The nomination represents the most definitive indication that the administration is attempting to move past its rhetoric questioning vaccine safety and efficacy as the November elections approach.
If confirmed by the Senate, Schwartz would become the agency's fourth leader in under a year and its second permanent director. Her nomination follows the abrupt dismissal of the previous Senate-confirmed director, Susan Monarez, by Health Secretary Robert F. Kennedy Jr. after a dispute over vaccine policy less than a month into her tenure.
A Team to 'Restore the Gold Standard of Science'
In a Truth Social post announcing the nomination, Trump praised Schwartz's credentials, highlighting her Ivy League education and military service. "She is a STAR!" he wrote. The president simultaneously named three other officials to top CDC roles: Sean Slovenski, former Walmart Health president, as Deputy Director and COO; Jennifer Shuford, Texas's health commissioner, as Deputy Director and CMO; and Sara Brenner from the FDA as Senior Counselor to Secretary Kennedy.
"These Highly Respected Doctors of Medicine have the knowledge, experience, and TOP degrees to restore the GOLD STANDARD OF SCIENCE at the CDC," Trump stated. The appointments aim to stabilize an agency that has faced severe turbulence, including mass firings, budget reductions, a headquarters shooting, and public criticism from Kennedy, who has previously labeled the institution as corrupt.
Schwartz Seen as Credible, Apolitical Choice
Schwartz is widely viewed as a conventional selection for the role. She lacks a public record of vaccine opposition and has no apparent ties to the Make America Healthy Again (MAHA) movement, which has championed vaccine skepticism. Her background includes serving as chief medical officer for the U.S. Coast Guard, where she managed disease surveillance and authored policies for pandemic influenza and Ebola outbreaks.
Jerome Adams, Trump's former Surgeon General who personally selected Schwartz as his deputy, endorsed the nomination. "A battle-tested leader with decades of distinguished public service... she has the expertise, credibility, and integrity to lead the CDC effectively," Adams posted on social media. He added, "If allowed to follow the science without political interference, she'll excel."
David Mansdoerfer, a former senior HHS official in the first Trump term, called Schwartz "the perfect pick" to stabilize an agency that has been "on its haunches since the COVID response." He urged MAHA activists to give her a chance, describing her as open-minded and evidence-driven.
Political Recalibration Ahead of Midterms
The nomination coincides with a White House effort to moderate Kennedy's vaccine-focused policies before voters head to the polls. Internal polling reportedly shows public support for vaccines and disapproval of the administration's previous moves. A December memo from Trump pollster Tony Fabrizio warned that "skepticism toward vaccine requirements is politically risky," while noting other MAHA priorities like food safety remain popular.
The administration now seeks to pivot public attention toward broadly popular issues like drug pricing and the less contentious aspects of the MAHA agenda. This strategic shift occurs even as Kennedy continues policy actions that reduce vaccine access. He dismissed a key CDC advisory panel on immunizations, replacing experts with his own appointees who have questioned vaccine safety, and unilaterally overhauled the childhood vaccine schedule to recommend fewer shots. A federal judge blocked these moves last month, and the administration has not appealed.
Kennedy has recently softened his public rhetoric on vaccines, despite these actions. At a House appropriations hearing just before Trump's announcement, Kennedy praised the new CDC team, claiming it has "gotten applause from both Republicans and Democrats" and will "revolutionize CDC and get it back on track." This nomination, alongside other administration moves like extending a waiver on Russian oil sanctions and escalating a feud with Federal Reserve Chair Jerome Powell, illustrates the complex political calculations defining Trump's pre-election governance.
